206 related articles for article (PubMed ID: 35114947)
1. Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes.
Olbertova H; Plevova K; Pavlova S; Malcikova J; Kotaskova J; Stranska K; Spunarova M; Trbusek M; Navrkalova V; Dvorackova B; Tom N; Pal K; Jarosova M; Brychtova Y; Panovska A; Doubek M; Pospisilova S
BMC Cancer; 2022 Feb; 22(1):137. PubMed ID: 35114947
[TBL] [Abstract][Full Text] [Related]
2. Telomere status in chronic lymphocytic leukemia with TP53 disruption.
Guièze R; Pages M; Véronèse L; Combes P; Lemal R; Gay-Bellile M; Chauvet M; Callanan M; Kwiatkowski F; Pereira B; Vago P; Bay JO; Tournilhac O; Tchirkov A
Oncotarget; 2016 Aug; 7(35):56976-56985. PubMed ID: 27486974
[TBL] [Abstract][Full Text] [Related]
3. Short telomeres are associated with inferior outcome, genomic complexity, and clonal evolution in chronic lymphocytic leukemia.
Jebaraj BMC; Tausch E; Landau DA; Bahlo J; Robrecht S; Taylor-Weiner AN; Bloehdorn J; Scheffold A; Mertens D; Böttcher S; Kneba M; Jäger U; Zenz T; Wenger MK; Fingerle-Rowson G; Wendtner C; Fink AM; Wu CJ; Eichhorst B; Fischer K; Hallek M; Döhner H; Stilgenbauer S
Leukemia; 2019 Sep; 33(9):2183-2194. PubMed ID: 30911113
[TBL] [Abstract][Full Text] [Related]
4. Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.
Hoxha M; Fabris S; Agnelli L; Bollati V; Cutrona G; Matis S; Recchia AG; Gentile M; Cortelezzi A; Morabito F; Bertazzi PA; Ferrarini M; Neri A
Genes Chromosomes Cancer; 2014 Jul; 53(7):612-21. PubMed ID: 24706380
[TBL] [Abstract][Full Text] [Related]
5. Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations.
Damle RN; Batliwalla FM; Ghiotto F; Valetto A; Albesiano E; Sison C; Allen SL; Kolitz J; Vinciguerra VP; Kudalkar P; Wasil T; Rai KR; Ferrarini M; Gregersen PK; Chiorazzi N
Blood; 2004 Jan; 103(2):375-82. PubMed ID: 14504108
[TBL] [Abstract][Full Text] [Related]
6. Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation.
Bracher S; Fuhrmann I; Jeromin S; Nadarajah N; Kern W; Haferlach T; Haferlach C; Stengel A
Mol Biol Rep; 2022 Dec; 49(12):12247-12252. PubMed ID: 36169893
[TBL] [Abstract][Full Text] [Related]
7. Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.
Thomay K; Fedder C; Hofmann W; Kreipe H; Stadler M; Titgemeyer J; Zander I; Schlegelberger B; Göhring G
Ann Hematol; 2017 Sep; 96(9):1493-1500. PubMed ID: 28691153
[TBL] [Abstract][Full Text] [Related]
8. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes.
Rampazzo E; Bonaldi L; Trentin L; Visco C; Keppel S; Giunco S; Frezzato F; Facco M; Novella E; Giaretta I; Del Bianco P; Semenzato G; De Rossi A
Haematologica; 2012 Jan; 97(1):56-63. PubMed ID: 21933855
[TBL] [Abstract][Full Text] [Related]
9. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.
Malcikova J; Stano-Kozubik K; Tichy B; Kantorova B; Pavlova S; Tom N; Radova L; Smardova J; Pardy F; Doubek M; Brychtova Y; Mraz M; Plevova K; Diviskova E; Oltova A; Mayer J; Pospisilova S; Trbusek M
Leukemia; 2015 Apr; 29(4):877-85. PubMed ID: 25287991
[TBL] [Abstract][Full Text] [Related]
10. Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications.
Hultdin M; Rosenquist R; Thunberg U; Tobin G; Norrback KF; Johnson A; Sundström C; Roos G
Br J Cancer; 2003 Feb; 88(4):593-8. PubMed ID: 12592375
[TBL] [Abstract][Full Text] [Related]
11. Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.
Malcikova J; Pavlova S; Kunt Vonkova B; Radova L; Plevova K; Kotaskova J; Pal K; Dvorackova B; Zenatova M; Hynst J; Ondrouskova E; Panovska A; Brychtova Y; Zavacka K; Tichy B; Tom N; Mayer J; Doubek M; Pospisilova S
Blood; 2021 Dec; 138(25):2670-2685. PubMed ID: 33945616
[TBL] [Abstract][Full Text] [Related]
12. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
13. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia.
Ouillette P; Saiya-Cork K; Seymour E; Li C; Shedden K; Malek SN
Clin Cancer Res; 2013 Jun; 19(11):2893-904. PubMed ID: 23620403
[TBL] [Abstract][Full Text] [Related]
14. Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia.
Roos G; Kröber A; Grabowski P; Kienle D; Bühler A; Döhner H; Rosenquist R; Stilgenbauer S
Blood; 2008 Feb; 111(4):2246-52. PubMed ID: 18045969
[TBL] [Abstract][Full Text] [Related]
15. Telomere length, telomerase expression, and oxidative stress in lead smelters.
Pawlas N; Płachetka A; Kozłowska A; Mikołajczyk A; Kasperczyk A; Dobrakowski M; Kasperczyk S
Toxicol Ind Health; 2016 Dec; 32(12):1961-1970. PubMed ID: 26381690
[TBL] [Abstract][Full Text] [Related]
16. Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population.
Song DY; Kim JA; Jeong D; Yun J; Kim SM; Lim K; Park SN; Im K; Choi S; Yoon SS; Lee DS
PLoS One; 2019; 14(7):e0220177. PubMed ID: 31335885
[TBL] [Abstract][Full Text] [Related]
17. Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia.
Brezinova J; Berkova A; Vcelikova S; Zemanova Z; Izakova S; Sarova I; Cechova H; Tajtlova J; Grosova L; Lizcova L; Malinova E; Zemanova M; Cmunt E; Karban J; Trneny M; Schwarz J; Michalova K
Neoplasma; 2010; 57(3):215-21. PubMed ID: 20353271
[TBL] [Abstract][Full Text] [Related]
18. Do telomeres have a higher plasticity than thought? Results from the German Chronic Kidney Disease (GCKD) study as a high-risk population.
Raschenberger J; Kollerits B; Titze S; Köttgen A; Bärthlein B; Ekici AB; Forer L; Schönherr S; Weissensteiner H; Haun M; Wanner C; Eckardt KU; Kronenberg F;
Exp Gerontol; 2015 Dec; 72():162-6. PubMed ID: 26423240
[TBL] [Abstract][Full Text] [Related]
19. Examination of clonal evolution in chronic lymphocytic leukemia.
Koczkodaj D; Popek-Marciniec S; Zmorzyński S; Wąsik-Szczepanek E; Filip AA
Med Oncol; 2019 Aug; 36(9):79. PubMed ID: 31375939
[TBL] [Abstract][Full Text] [Related]
20. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia.
Bechter OE; Eisterer W; Pall G; Hilbe W; Kühr T; Thaler J
Cancer Res; 1998 Nov; 58(21):4918-22. PubMed ID: 9810000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
